Compare FMC Corp (FMC) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Koninklijke Philips NV — how do they compare? FMC Corp trades at $11.46 (market cap $1.36B), while Koninklijke Philips NV trades at $27.15 (market cap $26.29B). The key difference: Koninklijke Philips NV is far larger — about 19.3× FMC Corp's market cap, and Koninklijke Philips NV pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| FMC | PHG | |
|---|---|---|
Market Cap | $1.36B | $26.29B |
Sector | Basic Materials | Health |
52-Week High | $43.90 | $32.91 |
52-Week Low | $10.72 | $24.38 |
Enterprise Value | $5.50B | $32.56B |
Dividend Yield | 2.95% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC Corporation (FMC) trades at $10.72, down 1.74% on the day, reflecting ongoing challenges despite recent strategic moves. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal significant pressure with a net income margin of -72.93% and negative ROE of -80.78% for 2025. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide rimisoxafen, providing some operational support amid financial restructuring.
The outlook remains cautious with analyst consensus leaning neutral (50% Hold) despite a $16 price target suggesting 49% upside. Key risks include persistent revenue declines, high debt levels, and negative cash flow from operations. Investment opportunity exists if new product approvals and debt reduction efforts successfully stabilize profitability, but current financial metrics indicate substantial execution risk near term.
Royal Philips (PHG) trades at $26.06, down 4.68% today, with bearish technical signals but improving fundamentals. The company reported strong Q1 2026 earnings beat and maintains a 5.5% net income margin. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships highlight innovation momentum. Cash flow remains positive at $403M for 2025, though debt-to-asset ratio increased to 25.44%.
PHG shows recovery potential with earnings growth and AI healthcare adoption, but faces execution risks and technical weakness. Analyst consensus leans Hold (59%) with no Sell ratings, suggesting cautious optimism. Key risks include competitive pressures and macroeconomic volatility affecting medical equipment demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
